Skip to main content

Table 3 Grade ≥ 3 treatment-emergent adverse events in ≥10% of patients

From: Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study

Grade ≥ 3 adverse events, n (%)

nab-P + Gem

N = 83

Pts with at least 1 grade ≥ 3 AE

62 (75)

Hematologic AEsa

 Leukopenia

28 (35)

 Neutropenia

27 (34)

 Anemia

12 (15)

 Thrombocytopenia

8 (10)

Nonhematologic AEs

 Fatigue

11 (13)

  1. AE adverse event, Gem gemcitabine, nab-P nab-paclitaxel
  2. aBased on laboratory values; n = 80 patients assessed
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us